Zobrazeno 1 - 5
of 5
pro vyhledávání: ''
Publikováno v:
E-Posters.
Objectives Ovarian cancer is one of the highest incidence and mortality gynecological tumors. Most of them will relapse within 24 months. The purpose of this study was to compare the efficacy and safety of doxorubicin liposomes or paclitaxel combined
Autor:
I Braicu, Christina Fotopoulou, C. Buschmann, Michael Hummel, Klaus Pietzner, Jalid Sehouli, Radoslav Chekerov, BD Nguyen-Sträuli, J. Baum, P. Meyer-Wilmes, A. Kreklau, S Boz
Publikováno v:
Ovarian cancer.
Introduction/Background* Poly(ADP-ribose) polymerase inhibitors (PARPi) have been approved for several tumor entities including epithelial ovarian cancer (EOC). The purpose of the study is to analyze the current implementation of BRCA testing and PAR
Autor:
B Gregorič
Publikováno v:
Poster.
Introduction Bevacizumab is used in advanced epithelial ovarian cancer patients as a part of standard primary systemic therapy together with paclitaxel and carboplatin combination chemotherapy since 2013. Aim of study To evaluate safety and efficacy
Autor:
D Lambrechts, P. Berteloot, A Vanderstichele, E Van Nieuwenhuysen, P Busschaert, T. Van Gorp, Nicole Concin, T Callewaert, Ignace Vergote, Sileny Han, P Neven
Publikováno v:
Poster exhibition Day 2.
Introduction/Background Patients with relapsed ovarian cancer receive multiple lines of chemotherapy, each negatively affecting their health-related quality of life (HRQOL). The CLIO trial randomized patients with platinum-resistant relapsed ovarian
Autor:
S Khokhlova
Publikováno v:
ePoster.
Introduction/Background Experience of repeated use of maintenance therapy olaparib in patients with platinum-sensitive relapse of ovarian cancer in patients with a BRCA1 or BRCA2 (BRCA1/2) mutation. Methodology In pilot trial evaluated olaparib capsu